Avadel Pharma Q2 revenue up 64%, raises 2025 guidance

Avadel Pharmaceuticals

07/08/2025 12:29

Overview

Avadel Q2 net revenue rises 64% yr/yr, driven by LUMRYZ growth

Company reports first net income since LUMRYZ launch, totaling $9.7 mln

Raises 2025 full-year revenue guidance to $265-$275 mln

Outlook

Avadel raises 2025 full-year revenue guidance to $265-$275 mln

Company expects Q3 2025 revenue of $71-$75 mln

Avadel forecasts Q3 2025 cash operating expenses of $50-$55 mln

Result Drivers

PATIENT GROWTH - 63% increase in patients on LUMRYZ compared to June 2024

COMMERCIAL INVESTMENTS - Strong commercial execution and investments driving favorable uptake and persistency trends

ORPHAN DRUG DESIGNATION - FDA designation for LUMRYZ in idiopathic hypersomnia may boost future clinical advantage

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Product Revenue
$68.13 mln
Q2 EPS
$0.1
Q2 Net Income
$9.66 mln
Q2 Basic EPS
$0.1
Q2 Operating Expenses
$52.88 mln
Q2 Operating Income
$8.88 mln
Q2 Pretax Profit
$6.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $16.50, about 32.7% above its August 6 closing price of $11.10

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nGNX49JvPQ

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)